Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation - Contacts and Locations

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

This study is ongoing, but not recruiting participants.

Study NCT00016068. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00016068

Locations


United States, California
	City of Hope Comprehensive Cancer Center
	Duarte, California, United States, 91010-3000

United States, Florida
	University of Florida Shands Cancer Center
	Gainesville, Florida, United States, 32610-0232

United States, Michigan
	Barbara Ann Karmanos Cancer Institute
	Detroit, Michigan, United States, 48201-1379

United States, Minnesota
	Mayo Clinic Cancer Center
	Rochester, Minnesota, United States, 55905

United States, New York
	Memorial Sloan-Kettering Cancer Center
	New York, New York, United States, 10021

United States, Texas
	M.D. Anderson Cancer Center at University of Texas
	Houston, Texas, United States, 77030-4009

United States, Washington
	Fred Hutchinson Cancer Research Center
	Seattle, Washington, United States, 98109-1024

Sponsors and Collaborators

Fred Hutchinson Cancer Research Center

National Cancer Institute (NCI)

Investigators


Study Chair:	Michael Boeckh, MD	Fred Hutchinson Cancer Research Center